

SGN-STNV

An investigational antibody-drug conjugate directed to STn

Anti-STn antibody


Monoclonal antibody that binds to STn

MMAE

Microtubule-disrupting agent

Protease-cleavable mc-vc linker

Covalently attaches MMAE to the antibody and releases agent within the target cell



Target: STn

- Carbohydrate antigen expressed on multiple cell surface tumor-associated glycoproteins¹⁻⁴
- STn expression in normal tissue is rare but is elevated in solid tumors, including pancreatic, ovarian, colorectal, cervical, breast, and lung adenocarcinomas^{3,5}
- Correlated with poor prognosis and chemotherapy resistance⁴

Proposed Mechanism of Action^{4,6,a}


- Direct cytotoxicity
- Immunogenic cell death
- Antibody-dependent cellular phagocytosis
- Bystander effect

mc-vc: maleimidocaproyl-valine-citrulline; **MMAE:** monomethyl auristatin E; **STn:** Sialyl Thomsen-nouveau

^aBased on preclinical data


1. Schultz MJ et al. Cancer Metastasis Rev. 2012: 501-18. 2. Pinho SS et al. Nat Rev Cancer. 2015: 540-50. doi:10.1038/nrc3982. 3. Eavarone DA et al. PLOS ONE. 2018: e0201314. 4. Schwartz A et al. AACR virtual 2021: Data presented. 5. Julien S et al. Biomolecules. 2012: 435-66. 6. Burton JK et al. AAPS J. 2019: 12.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.



Proposed Mechanism of Action^{1,2,a}

- 1 Binds to STn
- 2 Complex internalization and trafficking
- 3 MMAE release
- 4 Microtubule disruption
- 5 Cell cycle arrest and apoptotic cell death



MMAE: monomethyl auristatin E; **NK:** natural killer; **STn:** Sialyl Thomsen-nouveau

^aBased on preclinical data presented by A. Schwartz at AACR 2021

1. Schwartz A et al. AACR virtual 2021: Data presented. 2. Burton JK et al. AAPS J. 2019: 12.

Clinical Trials^a



RECRUITING

SGNSTNV-001: Advanced solid tumors (NCT04665921) SGN-STNV

Phase 1

Phase 2

Phase 3

Clinical trial information retrieved from clinicaltrials.gov, accessed Apr 2023.

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Seagen and its logo are US registered trademarks of Seagen Inc. Other trademarks are property of their respective owners.

For more information, contact us at:
+1-855-4SEAGEN (+1-855-473-2436)
medinfo@seagen.com / medinfoEU@seagen.com
www.seagenmedinfo.com